Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2026 earnings results
Rhythm Pharmaceuticals, Inc. (RYTM) reported Q3 2026 results on Nov 3, 2026, 8:10:02 AM ET: GAAP EPS -$0.61 vs. -$0.74 expected (beat by 17.8%); revenue $92.13M vs. $84.60M expected (beat by 8.9%). Outlook: Rhythm anticipates approximately $360 million to $380 million in Non-GAAP Operating Expenses for the year ending December 31, 2026.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (GAAP, diluted) | -$0.61 | -$0.74 | Beat by 17.8% |
| Revenue | $92.13M | $84.60M | Beat by 8.9% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Nov 3, 2026, 8:10:02 AM ET. Nexqual published them 37 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 79.6% from $51.30M; GAAP diluted EPS was -$0.61 vs. -$0.82 (+25.6%).
Stock reaction
The results came out before the market opened. RYTM closed at $86.44 on November 3, 2026, down 7.5% from its $93.44 close on November 2, 2026 before the results.
Questions and answers
Did Rhythm Pharmaceuticals, Inc. beat earnings expectations?
Yes. Rhythm Pharmaceuticals, Inc. reported GAAP EPS of -$0.61 against an average analyst estimate of -$0.74 (beat by 17.8%), and revenue of $92.13M against $84.60M expected (beat by 8.9%).
What were Rhythm Pharmaceuticals, Inc.'s Q3 2026 earnings and revenue?
GAAP diluted EPS of -$0.61 and revenue of $92.13M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 79.6% from $51.30M; GAAP diluted EPS was -$0.61 vs. -$0.82 (+25.6%).
When did Rhythm Pharmaceuticals, Inc. report Q3 2026 earnings?
Nov 3, 2026, 8:10:02 AM ET, in an SEC 8-K filing (Item 2.02).
How did RYTM stock react to the earnings?
The results came out before the market opened. RYTM closed at $86.44 on November 3, 2026, down 7.5% from its $93.44 close on November 2, 2026 before the results.
What did Rhythm Pharmaceuticals, Inc. say about its outlook?
Rhythm anticipates approximately $360 million to $380 million in Non-GAAP Operating Expenses for the year ending December 31, 2026.
More on RYTM
RYTM stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 3, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 4, 2026 at 10:46 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 4, 2026 at 10:46 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt